Log In
Print this Print this

Letairis, Volibris, ambrisentan

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionSelective endothelin A receptor antagonist
Molecular Target Endothelin A receptor
Mechanism of ActionEndothelin A receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHypertension
Indication DetailsTreat chronic thromboembolic pulmonary hypertension (CTEPH); Treat pulmonary arterial hypertension (PAH); Treat pulmonary arterial hypertension (PAH) in patients who previously failed other therapies; Treat pulmonary hypertension (PH)
Regulatory Designation U.S. - Orphan Drug (Treat pulmonary arterial hypertension (PAH));
Japan - Orphan Drug (Treat chronic thromboembolic pulmonary hypertension (CTEPH))
PartnerGlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today